NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note published on Friday. The brokerage issued a hold rating on the stock.

Separately, Ascendiant Capital Markets decreased their price objective on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Performance

Shares of NBY opened at $0.63 on Friday. The business has a 50-day moving average of $0.64 and a 200 day moving average of $0.62. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $9.08. The firm has a market cap of $3.08 million, a P/E ratio of -0.01 and a beta of 0.67.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.